Table 5.
Expression of cyclin D1 in parathyroid tumours and tissues.
| Pattern | Absolute Numbers of Pattern-Showing/Investigated Cases; Proportion of Positive Cases (%) or Fraction of Positive Cells (%) | |||||
|---|---|---|---|---|---|---|
| Parathyroid Carcinoma | Atypical Parathyroid Tumour | Adenoma | Multiglandular Parathyroid Disease | Normal Gland | Reference | |
| Mean value of strong nuclear expression | 31.5% | 12.0% | 24.8% PPH 1 | 10.1% | Uljanovs et al., 2021 [38] | |
| Highest (hotspot) value of strong nuclear expression | 41.8% | 22.8% | 42.5% PPH 1 | 11.9% | Uljanovs et al., 2021 [38] | |
| Nuclear expression exceeding 5% | 7/10; 70.0% | 10/14 AA 2; 71.4% | 5/21; 23.8% | Sungu et al., 2018 [79] | ||
| Lack of expression considered as the carcinoma-associated pattern | 2/24; 8.3% | Truran et al., 2014 [57] | ||||
| Nuclear expression exceeding 5% | 2/11; 18.2% | 1/8 AA 2; 12.5% | 4/44; 9.1% | Stojadinovic et al., 2003 [92] | ||
| Strong nuclear expression exceeding 20% | 2/2; 100.0% | 11/17; 64.7% | 0/10; 0.0% | Thomopoulou et al., 2003 [81] | ||
| Mean value of strong nuclear expression | 27.4% in joint group of carcinoma and adenoma | 27.4% in joint group of carcinoma and adenoma | 14.5% in PPH 1 3.7% in SPH 3 | <1% | Thomopoulou et al., 2003 [81] | |
| Nuclear expression | 41/46; 89.1% | 9/10; 90.0% | Cristobal et al., 2000 [104] | |||
| Mean value of nuclear expression | 25.8% | 27.1% | Cristobal et al., 2000 [104] | |||
| More than 10% of cells in adenoma stained more intensively than non-tumour cells | 9/24 (7, nuclear; 2, cytoplasmic); 37.5% |
Ikeda et al., 2002 [105] | ||||
In the original sources, different terms have been used in accordance with the actual classifications and terminology at the time of publication: 1 PPH, primary parathyroid hyperplasia; 2 AA, atypical adenoma; 3 SPH, secondary parathyroid hyperplasia.